AtriCure (ATRC) Set to Release Quarterly Earnings on Tuesday

AtriCure (NASDAQ:ATRC) is expected to be posting its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.0485) per share and revenue of $151.05 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

AtriCure Stock Performance

Shares of AtriCure stock opened at $60.87 on Tuesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. AtriCure has a one year low of $25.36 and a one year high of $61.70. The company has a market cap of $3.10 billion, a PE ratio of 289.85 and a beta of 1.24. The business has a 50-day simple moving average of $54.36 and a 200-day simple moving average of $37.75.

Analyst Ratings Changes

ATRC has been the topic of a number of analyst reports. Zacks Research cut AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 24th. Freedom Capital lowered shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 2nd. Weiss Ratings raised shares of AtriCure from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Needham & Company LLC upped their price target on shares of AtriCure from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Wednesday, September 2nd. Finally, Stifel Nicolaus set a $65.00 price target on shares of AtriCure in a research note on Thursday, September 17th. Six research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $55.70.

Insider Activity

In related news, Director Karen Prange sold 3,564 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total value of $138,283.20. Following the sale, the director owned 22,809 shares in the company, valued at $884,989.20. This represents a 13.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Justin J. Noznesky sold 6,182 shares of AtriCure stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total value of $239,861.60. Following the transaction, the insider directly owned 100,219 shares of the company’s stock, valued at approximately $3,888,497.20. This represents a 5.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 43,868 shares of company stock valued at $2,138,617 over the last three months. 4.00% of the stock is currently owned by corporate insiders.

About AtriCure

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.